The expression of C/EBPβ and STAT3 correlates with the mesenchymal phenotype of GBM and predicts poor clinical outcome and these two TF have been demonstrated to regulate the mesenchymal transformation of glioma cells [15, 16]. The gene discussed is CEBPB; the disease is central nervous system cancer.